This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (173) Depression and Mood Disorders; Suicide Prevention (1375) Gastroenterology and Hepatology (70)

Published on in Vol 10, No 9 (2021): September

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/31439, first published .
The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study

The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study

The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study

Authors of this article:

Arthi Chinna Meyyappan1, 2, 3, 4 Author Orcid Image ;   Cassandra Sgarbossa1, 2, 3 Author Orcid Image ;   Gustavo Vazquez1, 2, 3 Author Orcid Image ;   David J Bond5 Author Orcid Image ;   Daniel J Müller4, 6 Author Orcid Image ;   Roumen Milev1, 2, 3, 7 Author Orcid Image
Article Authors Cited by (8) Tweetations (11) Metrics

Journals

  1. Han W, Wang N, Han M, Ban M, Sun T, Xu J. Reviewing the role of gut microbiota in the pathogenesis of depression and exploring new therapeutic options. Frontiers in Neuroscience 2022;16 View
  2. Alshrari A, Hudu S, Elmigdadi F, Imran M. The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects. Biomedicines 2023;11(2):426 View
  3. Mörkl S, Butler M, Lackner S. Advances in the gut microbiome and mood disorders. Current Opinion in Psychiatry 2023;36(1):1 View
  4. Li S, Zhang Y. Sensitive delivery systems and novel encapsulation technologies for live biotherapeutic products and probiotics. Critical Reviews in Microbiology 2024;50(3):371 View
  5. Varesi A, Campagnoli L, Chirumbolo S, Candiano B, Carrara A, Ricevuti G, Esposito C, Pascale A. The brain-gut-microbiota interplay in depression: A key to design innovative therapeutic approaches. Pharmacological Research 2023;192:106799 View
  6. Bahmani M, Mehrtabar S, Jafarizadeh A, Zoghi S, Heravi F, Abbasi A, Sanaie S, Rahnemayan S, Leylabadlo H. The Gut Microbiota and Major Depressive Disorder: Current Understanding and Novel Therapeutic Strategies. Current Pharmaceutical Biotechnology 2024;25(16):2089 View
  7. Chen L, Cao H, Zhang X, Du X, Guan Y, Li M, Chang A, He X, Li X, Bi X. Antidepressant effects of sulforaphane (SFN) and its derivatives SLL-III-9 and SLL-III-120 and their potential underlying mechanisms based on the microbiota–gut–brain axis. Food & Function 2024;15(20):10539 View
  8. Daisley B, Allen‐Vercoe E. Microbes as medicine. Annals of the New York Academy of Sciences 2024;1541(1):63 View